Coherus’ Lucentis Biosimilar Outstrips Biogen Rival One Month After Launch

$100m In Cimerli Revenues Anticipated In 2023, Q Code Submitted

 
• By Dean Rudge
  
Iurii Kirsanov/Alamy Stock Photo
Coherus has raced ahead of the competition • Source: Shutterstock (Iurii Kirsanov / Alamy Stock Pho/Alamy Stock Photo)
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products